I see the stars aligning for Rvx and Zen

Imagine the PhaseIII trial meeting or exceeding the 30% MACE reduction in Europe as US recruitment and testing unfolds and prostate combo trial for Zenith enters next phase followed by start of next phase of ckd trial & public awakening to Epigenetics - a world where ckd may be treated at 20% of the cost of dialysis, and the same compound chases latent HIV from the shadows where it is unmasked and cured - a Zenith IPO - it's coming together - in an environment where lower tax rates  spurn  productivity, cost efficiency, innovation, lower health care costs - I must be dreaming :-)

But maybe not - 2018 here we come!

Chicagoest